Passive lipoidal diffusion and carrier-mediated cell uptake are both important mechanisms of membrane permeation in drug disposition.

Recently, it has been proposed that drug permeation is essentially carrier-mediated only and that passive lipoidal diffusion is negligible. This opposes the prevailing hypothesis of drug permeation through biological membranes, which integrates the contribution of multiple permeation mechanisms, including both carrier-mediated and passive lipoidal diffusion, depending on the compound's properties, membrane properties, and solution properties. The prevailing hypothesis of drug permeation continues to be successful for application and prediction in drug development. Proponents of the carrier-mediated only concept argue against passive lipoidal diffusion. However, the arguments are not supported by broad pharmaceutics literature. The carrier-mediated only concept lacks substantial supporting evidence and successful applications in drug development.

[1]  Michael H. Abraham,et al.  Scales of solute hydrogen-bonding: their construction and application to physicochemical and biochemical processes , 2010 .

[2]  P. Elias,et al.  In situ precipitation: a novel cytochemical technique for visualization of permeability pathways in mammalian stratum corneum. , 1980, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[3]  P. Artursson,et al.  Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  Stina Syvänen,et al.  On The Rate and Extent of Drug Delivery to the Brain , 2007, Pharmaceutical Research.

[5]  M. Kansy,et al.  Hydrogen-Bonding Capacity and Brain Penetration , 1992, Chimia (Basel).

[6]  M. Uhlén,et al.  Endogenous Gene and Protein Expression of Drug-Transporting Proteins in Cell Lines Routinely Used in Drug Discovery Programs , 2009, Drug Metabolism and Disposition.

[7]  S. Micelli,et al.  Non-electrolyte permeability across thin lipid membranes. , 1971, Archives internationales de physiologie et de biochimie.

[8]  R. Reigada.  Atomistic Study of Lipid Membranes Containing Chloroform: Looking for a Lipid-Mediated Mechanism of Anesthesia , 2013, PloS one.

[9]  Bernard Testa,et al.  Quantitative Structure-Permeation Relationships (QSPeRs) to Predict Skin Permeation: A Critical Evaluation , 2004, Pharmaceutical Research.

[10]  Abraham White,et al.  The Permeability of Natural Membranes , 1944, The Yale Journal of Biology and Medicine.

[11]  G. Wittum,et al.  Non Steady-state Descriptions of Drug Permeation Through Stratum Corneum. I. The Biphasic Brick-and-Mortar Model , 1996, Pharmaceutical Research.

[12]  R Iwata,et al.  Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. , 2001, British journal of clinical pharmacology.

[13]  Alex Avdeef,et al.  How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? , 2010, Journal of medicinal chemistry.

[14]  B. Brodie,et al.  On the mechanism of intestinal absorption of drugs. , 1959, The Journal of pharmacology and experimental therapeutics.

[15]  David A. Powell,et al.  Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. , 2011, Journal of medicinal chemistry.

[16]  S. Apparsundaram,et al.  Unbound Brain Concentration Determines Receptor Occupancy: A Correlation of Drug Concentration and Brain Serotonin and Dopamine Reuptake Transporter Occupancy for Eighteen Compounds in Rats , 2009, Drug Metabolism and Disposition.

[17]  Douglas B Kell,et al.  Genome-wide assessment of the carriers involved in the cellular uptake of drugs: a model system in yeast , 2011, BMC Biology.

[18]  Bernard Testa,et al.  A simple model to predict blood-brain barrier permeation from 3D molecular fields. , 2002, Biochimica et biophysica acta.

[19]  The permeability of plant protoplasts to nonelectrolytes , 1938, Protoplasma.

[20]  Douglas B Kell,et al.  Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. , 2011, Drug discovery today.

[21]  P. Artursson,et al.  Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  K. Pettigrew,et al.  Drug entry into the brain , 1979, Brain Research.

[23]  Alex Avdeef,et al.  Absorption and drug development , 2003 .

[24]  Li Di,et al.  Coexistence of passive and carrier-mediated processes in drug transport , 2010, Nature Reviews Drug Discovery.

[25]  P. Hinderling,et al.  Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. , 1997, Pharmacological reviews.

[26]  P. Elias,et al.  Human epidermal lipids: characterization and modulations during differentiation. , 1983, Journal of lipid research.

[27]  D. O. Rudin,et al.  Reconstitution of Cell Membrane Structure in vitro and its Transformation into an Excitable System , 1962, Nature.

[28]  A. Avdeef,et al.  Physicochemical Selectivity of the BBB Microenvironment Governing Passive Diffusion—Matching with a Porcine Brain Lipid Extract Artificial Membrane Permeability Model , 2011, Pharmaceutical Research.

[29]  D. Landsittel,et al.  Regarding the sources of data analyzed with quantitative structure-skin permeability relationship methods (commentary on 'Investigation of the mechanism of flux across human skin in vitro by quantitative structure-permeability relationships'). , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[30]  Jing Chen,et al.  Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. , 2012, Journal of medicinal chemistry.

[31]  Michael S. Roberts,et al.  Epidermal permeability: Penetrant structure relationships. 2. The effect of h-bonding groups in penetrants on their diffusion through the stratum corneum , 1996 .

[32]  G P Moss,et al.  Investigation of the mechanism of flux across human skin in vitro by quantitative structure-permeability relationships. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[33]  R. Collander.  The permeability of plant protoplasts to non-electrolytes , 1937 .

[34]  U. Holzgrabe,et al.  Overton's Rule Helps To Estimate the Penetration of Anti-Infectives into Patients' Cerebrospinal Fluid , 2011, Antimicrobial Agents and Chemotherapy.

[35]  T. Fujita,et al.  Quantitative analysis of partition behavior of substituted phenols from aqueous phase into liposomes made of lecithin and various lipids , 1987 .

[36]  L. Ross,et al.  Biased Assimilation and Attitude Polarization: The Effects of Prior Theories on Subsequently Considered Evidence , 1979 .

[37]  Per Artursson,et al.  Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA method , 2005 .

[38]  P. Carrupt,et al.  Development of molecular hydrogen-bonding potentials (MHBPs) and their application to structure-permeation relations. , 2001, Journal of molecular graphics & modelling.

[39]  B. Testa,et al.  A Fresh Look at Molecular Structure and Properties , 2007 .

[40]  P A Carrupt,et al.  Evaluation and Prediction of Drug Permeation , 1999, The Journal of pharmacy and pharmacology.

[41]  A. Bangham.  Surrogate cells or Trojan horses. The discovery of liposomes. , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

[42]  D. Kell,et al.  Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? , 2008, Nature Reviews Drug Discovery.

[43]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[44]  R. Scheuplein,et al.  Permeability of the skin. , 1971, Physiological reviews.

[45]  D. Kell,et al.  The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. , 2013, Drug discovery today.

[46]  Friedrich Schuler,et al.  A liposomal fluorescence assay to study permeation kinetics of drug-like weak bases across the lipid bilayer. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[47]  T. Xiang,et al.  Influence of a Transmembrane Protein on the Permeability of Small Molecules Across Lipid Membranes , 2000, The Journal of Membrane Biology.

[48]  M. Abraham,et al.  Algorithms for Skin Permeability Using Hydrogen Bond Descriptors: the Problem of Steroids * , 1997, The Journal of pharmacy and pharmacology.

[49]  A. Beckett,et al.  Urinary Excretion of Methylamphetamine in Man , 1965, Nature.

[50]  D. Tosteson,et al.  Diffusion of Weak Acids across Lipid Bilayer Membranes: Effects of Chemical Reactions in the Unstirred Layers , 1973, Science.

[51]  Ismael Zamora,et al.  pH-Dependent Bidirectional Transport of Weakly Basic Drugs Across Caco-2 Monolayers: Implications for Drug–Drug Interactions , 2003, Pharmaceutical Research.

[52]  W. Stein,et al.  The Movement of Molecules Across Cell Membranes , 2012 .

[53]  P. Uzor,et al.  Perspectives on Transdermal Drug Delivery , 2011 .

[54]  A. Avdeef,et al.  P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[55]  R. King,et al.  New approach to pharmacophore mapping and QSAR analysis using inductive logic programming. Application to thermolysin inhibitors and glycogen phosphorylase B inhibitors. , 2002, Journal of medicinal chemistry.

[56]  K. Edashige,et al.  Rapid Movement of Water and Cryoprotectants in Pig Expanded Blastocysts via Channel Processes: Its Relevance to Their Higher Tolerance to Cryopreservation1 , 2013, Biology of reproduction.

[57]  Stephen A. Wring,et al.  Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[58]  P. Carrupt,et al.  Physicochemical properties and transport behaviour of piribedil: Considerations on its membrane-crossing potential , 1992 .

[59]  Michael S. Roberts,et al.  Epidermal permeability — Penetrant structure relationships: 3. The effect of hydrogen bonding interactions and molecular size on diffusion across the stratum corneum , 1996 .

[60]  B. Testa,et al.  Organic stereochemistry. Part 5 : Stereoselectivity in molecular and clinical pharmacology , 2013 .

[61]  P. Pohl,et al.  110 years of the Meyer-Overton rule: predicting membrane permeability of gases and other small compounds. , 2009, Chemphyschem : a European journal of chemical physics and physical chemistry.

[62]  G. Ecker,et al.  Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. , 2012, Drug discovery today.

[63]  Bernard Testa,et al.  Lipophilicity and Its Relationship with Passive Drug Permeation , 2011, Pharmaceutical Research.

[64]  Thomas Singer,et al.  In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. , 2012, Journal of medicinal chemistry.

[65]  I Meineke,et al.  Influence of urine pH and urinary flow on the renal excretion of memantine. , 1998, British journal of clinical pharmacology.

[66]  J. Diamond,et al.  Effects of unstirred layers on membrane phenomena. , 1984, Physiological reviews.

[67]  K. Jørgensen,et al.  A New Look at Lipid-Membrane Structure in Relation to Drug Research , 1998, Pharmaceutical Research.

[68]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[69]  Y. Kalia,et al.  TRANSDERMAL DRUG DELIVERY: Clinical Aspects , 1998 .

[70]  C. K. Chu,et al.  19F NMR study of the uptake of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil in erythrocytes: evidence of transport by facilitated and nonfacilitated pathways. , 1998, Biochemical pharmacology.

[71]  Ulf Bredberg,et al.  Measurement of Unbound Drug Exposure in Brain: Modeling of pH Partitioning Explains Diverging Results between the Brain Slice and Brain Homogenate Methods , 2011, Drug Metabolism and Disposition.

[72]  J. Axelrod,et al.  EFFECTS OF URINARY pH ON AMPHETAMINE METABOLISM , 1971, Annals of the New York Academy of Sciences.

[73]  J. Hadgraft,et al.  Percutaneous absorption: in vivo experiments , 1979, The Journal of pharmacy and pharmacology.

[74]  Alessandro Pedretti,et al.  Assessing drug-likeness--what are we missing? , 2008, Drug discovery today.

[75]  J. Hadgraft,et al.  The selection and design of topical and transdermal agents: a review. , 1998, The journal of investigative dermatology. Symposium proceedings.

[76]  P. Carrupt,et al.  Molecular fields in quantitative structure–permeation relationships: the VolSurf approach , 2000 .

[77]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[78]  Lauren E. Marbella,et al.  Observing the translocation of a mitochondria-penetrating peptide with solid-state NMR. , 2013, Biochimica et biophysica acta.

[79]  Douglas B Kell,et al.  Implications of the dominant role of transporters in drug uptake by cells. , 2009, Current topics in medicinal chemistry.